Home › Cancro gastrointestinali › Massachusetts › Boston
Studi clinici su Cancro gastrointestinali a Boston, MA
15 studi su Cancro gastrointestinali cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
In reclutamentoFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
In reclutamentoFase 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
In reclutamentoFase 3
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
In reclutamento
- Dana Farber Cancer Institute, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
In reclutamento
- Dana-Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
In reclutamentoFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
BOLSTER: Learning New Skills to Thrive
In reclutamento
- Dana-Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
In reclutamentoFase 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
Studi su Cancro gastrointestinali in altre città
- Houston, TX21 studi
- New York City, NY12 studi
- Nashville, TN10 studi
- Los Angeles, CA9 studi
- Dallas, TX8 studi
- Durham, NC8 studi
- Baltimore, MD8 studi
- Cincinnati, OH8 studi
- Arlington, VA8 studi
- San Antonio, TX7 studi
- Baldwin Park, CA7 studi
- Seattle, WA7 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.